Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
HRMY

HRMY - Harmony Biosciences Holdings, Inc. Stock Price, Fair Value and News

$36.82-0.86 (-2.28%)
Market Closed

87/100

HRMY

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

87/100

HRMY

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

$55.23

Target 3M

$42.64

Target 6M

$49.38

HRMY Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

HRMY Price Action

Last 7 days

0.4%

Last 30 days

-2.9%

Last 90 days

27.4%

Trailing 12 Months

-4.2%

HRMY RSI Chart

HRMY Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

HRMY Valuation

Market Cap

2.1B

Price/Earnings (Trailing)

11.42

Price/Sales (Trailing)

2.57

EV/EBITDA

6.6

Price/Free Cashflow

7.14

HRMY Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$55.23

Target 3M

$42.64

Target 6M

$49.38

HRMY Fundamentals

HRMY Revenue

Revenue (TTM)

825.9M

Rev. Growth (Yr)

28.71%

Rev. Growth (Qtr)

19.44%

HRMY Earnings

Earnings (TTM)

185.7M

Earnings Growth (Yr)

10.35%

Earnings Growth (Qtr)

27.88%

HRMY Profitability

EBT Margin

27.90%

Return on Equity

22.23%

Return on Assets

15.37%

Free Cashflow Yield

14%

HRMY Investor Care

Shares Dilution (1Y)

0.99%

Diluted EPS (TTM)

3.18

HRMY Alerts

  • 1 major insider sales recently.

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2025744.9M772.5M825.9M0
2024617.5M656.1M681.9M714.7M
2023471.7M498.9M541.9M582.0M
2022331.1M364.3M400.8M437.9M
2021199.6M235.4M270.5M305.4M
202044.4M82.9M121.3M159.7M
20190006.0M
Get all data in R, Python etc through our Historical Stock Data APIs

About Harmony Biosciences Holdings, Inc.

HRMY
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. It offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.
 CEO
 WEBSITEharmonybiosciences.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES200

Harmony Biosciences Holdings, Inc. Frequently Asked Questions

HRMY is the stock ticker symbol of Harmony Biosciences Holdings, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of Harmony Biosciences Holdings, Inc. is 2.12 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check HRMY's fair value in chart for subscribers.

The fair value guage provides a quick view whether HRMY is over valued or under valued. Whether Harmony Biosciences Holdings, Inc. is cheap or expensive depends on the assumptions which impact Harmony Biosciences Holdings, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for HRMY.

As of Wed Jan 28 2026, HRMY's PE ratio (Price to Earnings) is 11.42 and Price to Sales (PS) ratio is 2.57. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. HRMY PE ratio will change depending on the future growth rate expectations of investors.